Lymphocyte-mediated cytotoxicity in patients with renal and transitional cell carcinoma receiving BCG.
Our modified lymphocyte-mediated microcytotoxicity assay, which allows the serial estimation of lymphocyte cytotoxicity, was used to evaluate the immune response of patients with advanced renal cell and transitional cell carcinoma who were receiving BCG therapy. Preliminary data suggested that this assay may be useful in monitoring cancer patients receiving BCG.